Skip to main content

Table 4 Summary of previous and present studies investigating inappropriate prescriptions of dabigatran

From: Impact of Pharmacists’ audit on improving the quality of prescription of dabigatran etexilate methanesulfonate: a retrospective study

Authors [ref.] Country Design Number of patients Study patients IM (%) Bleeding rate (%) Comments
Armbruster et al. [12] USA R 458 I 16.6 14.4 -
Simon et al. [13] USA R 395 A 2 16 No serum creatinine levels were available within 1 week before and after the time of dabigatran initiation in 37% of patients.
Kimmons et al. [14] USA R 160 I 9a, 10b 3.8 aIndication and bdose. Only 61% of patients were newly initiated on dabigatran during the study period.
McDonald et al. [15] USA, Canada and Australia R 16,000 A 34.1–51.1 27.3–43.7 PIM was judged solely by co-administration of medicines potentially increase bleeding riskc
Larock et al. [16] Belgium P 69 I/A 49 14.7 MAI was used for assessing PIM
Basaran et al. [17] Turkey P 148 A 47 NA MAI was used for assessing PIM
Chowdhry et al. [18] Canada R 109 I 31.2 NA -
The present study Japan R 228 I/A I (11) vs. A (33) 7.7 Inappropriate prescription was judged according to the descriptions in prescribing information
  1. R retrospective chart review, P prospective study, I inpatients, A ambulant patients, MAI medication appropriate index, MAI is a tool designed to measure appropriateness of prescribing for people aged 65 years and older using 10 criteria comprising indication, choice, dosage, modalities and practicability of administration, drug-drug interaction and cost-effectiveness. [16, 17], IM inappropriate medication PIM potentially inappropriate medication, NA not available
  2. cselective serotonin reuptake inhibitor, non-steroidal anti-inflammatory drug, oral corticosteroids, systemic azole antifungals, macrolide antibiotics, HIV protease inhibitors, cyclosporine, dronedarone, tacrolimus, verapamil, amiodarone and quinidine